24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Anchiano
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:32
Covenant opens 10,000-square-meter German factory to build long-range weapons for Europe
22:19
HubSpot cuts nearly 660 jobs as AI reshapes its business
22:06
Palo Alto, CrowdStrike and Fortinet hit records as Wall Street’s AI fears fade
20:47
Israeli crypto trader arrested over alleged multimillion-dollar tax evasion scheme
More stories
Buzz
Most popular
Daily
Weekly
1
Capitolis raises $220 million from Wall Street giants at $1.9 billion valuation
2
Nikesh Arora says AI won’t cost Palo Alto engineers their jobs. Everyone else is “fair game”
3
“They condemn Israel publicly while quietly acquiring our air defense systems”
4
After attempted hijacking, Israel has changed no aviation security procedures
5
“Sapiens had a poor culture of failing to keep promises”: Advent’s Mike Ettling on layoffs, AI and a company reset
More news
Anchiano
2 stories about Anchiano
Anchiano Therapeutics Schedules TASE Delisting
14.03.19
|
Lilach Baumer
Based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer
Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq
09.01.19
|
Lilach Baumer
The company formerly known as BioCanCell submitted a prospectus to the SEC on Monday, with Oppenheimer & Co. as the sole underwriter